Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tasquinimod in Myelofibrosis (TasqForce)
NCT06605586Phase 2Recruiting
- Sponsor
- HOVON
- Start
- Feb 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of tasquinimod in myelofibrosis (MF), sponsored by HOVON. Primary endpoints: Spleen Volume Reduction >= 35% at 24 weeks and Dose Limiting Toxicity at 28 days. Started Feb 2025; status: recruiting.
02
Drugs
tasquinimod
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT06605586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06605586.